Jeffrey Wolf

Jeffrey Wolf is the founder and CEO of Elusys. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies founded on breakthrough ideas and technology.

Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and plays an active role in supporting the growth of his companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel biocompatible polymers and acquired by Medtronic; and NightHawk Biosciences (co-founder and founding CEO), the parent company of Scorpius Biomanufacturing, a CDMO service provider focused on the manufacture of large molecule biologics for clinical and commercial development.

Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law, and his B.A. from the University of Chicago where he graduated with honors in economics.

William L. Ostrander

Mr. Ostrander has over 22 years of experience in financial management at public and private companies. Mr. Ostrander previously served as Executive Director of Finance at Liquidia Technologies, a publicly-traded biopharmaceutical company. Prior to that, he served as Senior Director of Finance and Accounting at KBI Biopharma, a biopharmaceutical contract services company. He also served as Manager of Finance at LexisNexis Risk Solutions, a data analytics solutions company. Prior to that, he served as Controller of Seisint Inc., a private information products company that was acquired by LexisNexis. Other previous roles include Senior Manager of Finance and various other accounting and finance positions for Boca Research, a data communications hardware manufacturer. Mr. Ostrander holds a B.S. in Finance from Central Michigan University.

Michael Menezes, Ph.D.

Director of Program Management

As the Director of Program Management, Dr. Menezes leads the internal and external operational teams responsible for the production of obiltoxaximab and the delivery of the associated final drug product.

Ryan Kane

Ryan Kane is the Senior Director of Government Affairs and Business Development for Elusys, where he overseas federal and state government relations, public affairs initiatives, communications, and business development opportunities. Ryan is also the President of RK Strategies, Inc., a public affairs and political consultancy with clients spanning publicly-traded pharmaceutical, energy, and technology sectors, and a founding partner of RKS Capital Holdings, LLC, a boutique investment group. Ryan has advised U.S. Senators, Governors, and a half-dozen members of the U.S. House of Representatives.

Cindi Dillon

Karen Blodgett

Senior Director Program Management (Consultant)

Ms. Blodgett has over 40 years of experience in biologics product and drug development. She has developed new and novel gene expression systems, devised and implemented analytical testing and manufacturing process improvement strategies, and led cross functional teams engaged in development of biodefense drug candidates for FDA licensure. She holds a M.S. degree in Biotechnology from Johns Hopkins University and a B.S. in Biology / Microbiology from Salisbury State University

Chief Operating Officer

As Chief Operating Officer, Dr. Michalek leverages scientific, clinical, and program management expertise to drive organizational growth through the alignment of projects with corporate objectives, the identification of strategic risks, and the development of partnership opportunities.

Dr. Michalek received his Ph.D. in microbiology and immunology from Wake Forest University with a focus on redox regulation of T cell activation. Subsequent postdoctoral studies at Duke University included foundational studies on the metabolic regulation of T cell differentiation, while biochemical profiling work with Metabolon resulted in publications encompassing cancer, autoimmune disease, and diabetes. Dr. Michalek’s experience also includes oversight of early and late phase clinical trials across several treatment modalities (cell and gene therapy, immunotherapy, small molecule inhibitors) with previous roles as the therapeutic area head of oncology for Pharm-Olam, co-chair of the Gene Therapy Operational Center of Excellence at PPD, and project leadership within IQVIA and Chiltern.

With over 30 peer-reviewed publications, ~5,000 citations, a previous appointment to the NIH Biomarker Consortium steering committee for Inflammation and Immunity, and awards from the Cancer Research Institute and American Association of Immunologists, Dr. Michalek is committed to identifying and advancing medical breakthroughs.

Matthew M. Seavey, Ph.D.

Vice President of Business Development

As Vice President of Business Development, Matthew Seavey holds over a decade of preclinical drug development experience. Originally trained as an immunologist, Dr. Seavey is an expert in early drug development and has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas, including GI, CNS, immuno-oncology, respiratory, inflammation and cardio-metabolics. He has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, and Oncology Program Director at United Therapeutics. Dr. Seavey is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and founding of Oncoceutics. Most recently, Dr. Seavey served as Director of Preclinical Pharmacology for CinRx Pharma and founding partner of BioPoint Consulting, LLC. Dr. Seavey holds a B.S. in Microbiology from the University of Vermont, an M.Sc. and Ph.D. in Immunology from the University of Rochester, and an M.B.A. from West Chester University.

Jennifer White

Associate Director of Quality Assurance

As the Associate Director of Quality Assurance, Jennifer White oversees corporate quality and GMP compliance of internal and external operations associated with the production of obiltoxaximab and the final drug product.

David Taylor, Ph.D.

Senior Scientist – CMC

As Senior Scientist – CMC, Dr. Taylor is responsible for bioanalytical assay management and analysis to ensure the safety, efficacy, and quality of Elusys products. Leveraging over a decade of practical laboratory experience, Dr. Taylor provides technical insight and guidance to internal teams and external vendors to confirm the design, reporting, and validation of Elusys bioanalytical methods support regulatory and cGMP compliance.

Dr. Taylor obtained his Ph.D. in molecular biology and genomics from Cornell University where he studied establishment and maintenance epigenetic imprinting in mice. During his postdoctoral work at Yale University, Dr. Taylor investigated the epigenetic profile of specialized stem cells in the highly regenerative flatworm model system. He transitioned into industry as a translational scientist at Heat Biologics where he worked across research, clinical, and manufacturing functional teams to push forward preclinical and clinical large molecule assets in the oncology, autoimmunity, and biodefense space.

.